NeuroMetrix's stock soars in active trade after collaboration with GlaxoSmithKline on Quell


Volume topped 270,000 shares more than two hours before the open, compared with the full-day average of about 184,000 shares. Under terms of the collaboration, GlaxoSmithKline will acquire exclusive ownership of Quell technology for markets outside the U.S., while NeuroMetrix will retain exclusive ownership for the U.S. market.



from Biotech News